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Poly-lactic-co-glycolic acid (PLGA) is one of the most widely used synthetic polymers for development of delivery systems for
drugs and therapeutic biomolecules and as component of tissue engineering applications. Its properties and versatility allow it to
be a reference polymer in manufacturing of nano- and microparticles to encapsulate and deliver a wide variety of hydrophobic and
hydrophilic molecules. It additionally facilitates and extends its use to encapsulate biomolecules such as proteins or nucleic acids
that can be released in a controlled way.This review focuses on the use of nano/microparticles of PLGA as a delivery system of one
of the most commonly used growth factors in bone tissue engineering, the bone morphogenetic protein 2 (BMP2). Thus, all the
needed requirements to reach a controlled delivery of BMP2 using PLGA particles as a main component have been examined.The
problems and solutions for the adequate development of this system with a great potential in cell differentiation and proliferation
processes under a bone regenerative point of view are discussed.
1. Introduction
Bone regeneration is one of the main challenges facing us in
the daily clinic. Immediately after a tooth extraction, normal
biological processes remodel the alveolar bone limiting in
some cases the possibility of future implant placement.
Different strategies for the preservation of that bone have
been explored in recent years. Other conditions, such as
trauma, tumor resective surgery, or congenital deformities,
require even higher technical and biological requirements
to generate the necessary bony structure for the occlusal
rehabilitation of the patient. To overcome these anatomical
limitations in terms of bone volume, different approaches
have been proposed to either improve the implant osteoin-
tegration or to augment the bone anatomy where it will be
placed [1, 2]. Autogenous bone graft is still considered the
“gold standard” due to its osteogenic, osteoconductive, and
osteoconductive properties [3, 4]. However, it also presents
several limitations including the need for a second surgery,
limited availability, and morbidity in the donor area [5].
Therefore, other biomaterials such as allogeneic grafts, with
osteoconductivity and osteoinductive capacities [6, 7], and
xenogeneic grafts [8, 9] and alloplastic biomaterials [10],
with osseoconductive potential, were proposed. All these
materials, although acceptable, are not suitable in many
conditions and usually require additional consideration in
the decision process [11]. Additionally, the bone quantity and
quality that can be obtained with these materials are often
limited.
The use of bioactive molecules, alone or in combina-
tion with the previously described materials, has, therefore,
become amajor area of interest thanks to their high potential.
When using this kind of procedures, it is important to
consider (1) the delivery method and (2) the molecule itself.
Bioactive molecules can be transported into the defect area
as a solution or a gel, embedded in sponges, adhered to solid
scaffolds and, more recently, included in particles of different
sizes. Using these methods, PDGF (platelet-derived growth
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factor), FGF (fibroblast growth factor), IGF (insulin growth
factor), Runx2, Osterix (Osx), LIM domain mineralization
protein (LMP), BMP (bone morphogenic protein) and, more
recently, periostin have been proposed as potential candidates
for regeneration procedures within the oral cavity, including
bone and periodontal tissues [12, 13]. These molecules have
been tested alone or in combination with stem cells [14] using
several in vitro and in vivo strategies [15].
Consequently, within the context of this review, we intend
to review the delivery methods of bioactive molecules with
the purpose of bone regeneration, with a particular focus on
polymeric nano/microparticles, especially those with PLGA
as main component, to encapsulate the growth factor BMP-
2. An overview of the biological functions of bone morpho-
genetic proteins and an analysis of the different parameters
affecting the physicochemical properties of these systems are
presented. Synthesis method, particle size and morphology,
use of stabilizers and their incidence in the colloidal sta-
bility, protective function, and surface functionality will be
discussed. In addition, we explore the different strategies that
can be used to optimize the encapsulation efficiency and
release kinetics, main parameters that determine the correct
development of polymeric carriers used in tissue-engineered
bone processes.
2. BMPs: Action and Regulation
For bone regeneration, in particular, bone morphogenetic
growth factors (BMP) are probably the more tested group
of molecules. Since 1965, when Urist [16] showed that the
extracted bone BMPs could induce bone and cartilage forma-
tion when implanted in animal tissue, an increasing number
of reports have tested its in vivo application and biological
foundation when used in bone defects [17–19]. BMPs are
members of the TGF-𝛽 superfamily of proteins [20]. The
BMP family of proteins groups more than 20 homodimeric
or heterodimericmorphogenetic proteins, which functions in
many cell types and tissues, not all of them being osteogenic
[21]. BMPs can be divided into 4 subfamilies based on their
function and sequence, being BMP-2, BMP-4, and BMP-
7 the ones with osteogenic potential [21]. The actions of
BMPs include chondrogenesis, osteogenesis, angiogenesis,
and extracellular matrix synthesis [22]. Within this fam-
ily of proteins, BMP-2 has been the most studied. It has
osteoinductive properties that promote the formation of new
bone by initiating, stimulating, and amplifying the cascade
of bone formation through chemotaxis and stimulation
of proliferation and differentiation of the osteoblastic cell
lineage [5, 17, 19, 20].The absence of it, as studied in knockout
models, leads to spontaneous fractures that do not heal with
time [23]. In fact, other models have demonstrated that the
absence of either BMP-4 [24] or BMP-7 [25] do not lead to
bone formation and function impairmentwhich demonstrate
the compensatory effect produced by BMP-2 alone [26].
Many cell types in bone tissue produce BMPs, including
osteoprogenitor cells, osteoblasts, chrondrocytes, platelets,
and endothelial cells. This secreted BMP is then stored in the
extracellular matrix where it mostly interacts with collagen
type IV [27]. During the repair and remodeling processes,
BMPs
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Figure 1: Schematic representation of the main BMP molecular
pathway to osteogenesis. BMPs interact with cell surface receptors
I and II to activate Smads 1, 5, and 8. These activated Smads activate
Smad 4. All together as a protein complex activate Runx2, Dlx5, and
Osterix.
osteoclast resorptive activity induces the release of BMPs to
the medium so that they are suspended and can interact with
nearby cells to initiate the subsequent osteogenic process [28].
A BMP in the extracellular matrix binds to cell surface
receptors BMPR-I and BMPR-II and activates the Smad
cytoplasmic proteins or the MAPK pathway [29]. When
BMPR-I is activated, BMPR-II is recruited and activated
as well [30]. The activation of the complexes BMPR-I and
BMPR-II leads to the activation of several Smads (1, 5, and 8)
that also activate Smad 4 and they all form protein complexes
that are transported into the nucleus where Runx2, Dlx5,
and Osterix genes (important in osteogenesis) are activated
[26, 27] (Figure 1). Similarly, when the MAPK pathway
is activated, it leads to induction of Runx2 transcription
and, therefore, to bone differentiation [31]. A number of
extracellular and intracellular antagonists have also been
described, including noggin, chordin, and gremlin or Smads
6, 7, and 8b, respectively [32].
2.1. Clinical Use of BMP-2. Today, the BMP-2 is commercially
available under different brand names and concentrations. It
usually consists of a collagen absorbable sponge embedded
with recombinant human BMP-2. In 2002, it was approved
by the FDA as an alternative of autogenous bone grafting
in anterior lumbar interbody fusion [33]. Later, in 2007, the
FDA approved the use of rhBMP-2 as an alternative for
autogenous bone grafting in the increase of the alveolar crest
defects associated with the tooth extraction maxillary sinus
pneumatization [33].
Beside the applications in spine clinical studies, where
very high concentrations are used (AMPLIFY, rhBMP-2,
40mg), clinical studies have supported its use in the oral
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cavity. BMPs have been used in periodontal regeneration,
bone healing, implant osteointegration, oral surgery with
orthodontic purposes, bone pathology sequel repair, distrac-
tion osteogenesis, and endodontic reparative surgery [28, 34].
However, it has shownmore promising results in cases where
only bone tissue is to be regenerated, including preimplant
site development, sinus lift, vertical and horizontal ridge
augmentation, and dental implant wound healing [35]. In this
sense, it has been shown that the use of rhBMP-2 induced the
formation of bone suitable for placement of dental implants
and their osteointegration [36]. Furthermore, it appears that
the newly formed bone has similar properties to the native
bone and is, therefore, capable of supporting denture occlusal
forces [37]. In the particular case of sinus lifting, where bone
deficiency is greater and, therefore, supportive therapies can
be more helpful, a recent meta-analysis found a total of 3
human studies and 4 animal trials (Table 1) [38]. In summary,
the included studies concluded that rhBMP-2 induces new
bone formation with comparable bone quality and quantity
of newly formed bone to that induced by autogenous bone
graft. In some cases, even higher bone quality and quantity
have been reported [39].
Conversely, recent studies report severe complications
after its use [61]. Even more, high doses have also associated
with carcinogenic effects, which led the authors to emphasize
the need for better guidelines in BMP clinical use [62]. Not
so drastic, recent studies are highlighting the negative side
effects and risks of its application, making high emphasis
on potential bias of nonreproducible industry sponsored
research, especially when used in spinal fusion [44, 63, 64].
The use of rhBMP-2 has been shown to increase the risks for
wound complications and dysphagia with high effectiveness
and harms misrepresentation through selective reporting,
duplicate publication, and underreporting [44]. Specifically
in oral bone regenerative applications, a report in sinus lift
concluded that the use of BMP-2 promotes negative effects
on bone formation when combined with anorganic bovine
bone matrix versus anorganic bovine bone alone [41], in
contrast with previous reports and reviews [38]. Taking
together this information, it can be concluded that it is of
extreme importance to be careful with the clinical use of new
products, avoiding off-label applications. It is also important
to highlight the need for more and better clinical research.
To overcome these limitations, new strategies, such as
the use of ex vivo BMP-2-engineered autologous MSCs [65],
encapsulation of the protein in different biomaterials, or
delivery by gene therapy, are being explored in recent years.
The development of these technologies is based on some
biological facts. In vitro effects of BMPs are observed at very
low dosages (5–20 ng/mL), although current commercially
available rhBMPs are used in large dosages (up to 40mg of
some products) [28]. This is probably due to an intense pro-
teolytic consumption during the early postsurgical phases. It
is important to know the proper sequence of biological events
that lead to normal tissue healing. Then, this knowledge can
be used to intervene at the specific time frame where our
therapy is intended to act [15]. Effective bone formation, as
described above, is a sequential process.Therefore, the induc-
tive agent should be delivered at a maintained concentration
during a timeframe. In this sense, as in many other processes
in medicine, it has been recently demonstrated that long-
term release of BMP-2 is more effective than short-term over
a range of doses [51]. It is also important to note that the
role of other molecular pathways and crosstalk between the
different components playing in bone regeneration is not
perfectly understood yet, and, therefore, more research has
to be conducted.
What is known so far, in summary, is that BMPs, specif-
ically BMP-2, is of utility for promoting bone regeneration
[28]. However, the currently FDA-approved BMP-2 delivery
system (INFUSE, Medtronic Sofamor Danek, Inc.) presents
important limitations [66]. Firstly, protein is quickly inacti-
vated.Therefore, its biological action disappears, maybe even
before the blood clot that forms after the surgery is being
organized. Second, the recombinant protein is delivered in
an absorbable collagen sponge. Thus, the distribution of
the BMP in a liquid suspension embedded into a collagen
sponge makes it impossible to be certain that the protein is
reaching the ideal target. Therefore, where, when, and for
how long a dose of BMP-2 is reached (determined by the
delivery method) are important factors. Because of that, new
forms of BMP-2 delivery are being developed. These new
technologies have to guarantee a higher half-life of the protein
and a stepped release, to increase the effects on the desired
cell targets. The biotechnology opens the door to be able to
provide a solution to these limitations.
Biodegradable nanoparticles (nanospheres and nanocap-
sules) have developed as a promising important tool for
the delivery of macromolecules via parenteral, mucous, and
topical applications [67–70]. Well-established biodegradable
polymers such as poly(acid D, L-lactic) or poly(D, L-lactic-
co-glycolic) have been widely used in the preparation of
nanoparticles in recent decades because of its biocompati-
bility and full biodegradability [71]. However, it is known
that certain macromolecules, such as proteins or peptides,
may lose activity during their encapsulation, storage, delivery,
and release [72]. To overcome this problem, the addition of
stabilizers such as oxide polyethylene (PEO) or the coencap-
sulation with other macromolecules and its derivatives seem
to be a promising strategy.
3. Polymeric Colloidal Particles to Encapsulate
Hydrophilic Molecules
Generally, polymeric colloidal particles are hard systems
with a homogeneous spherical shape composed by natural
or synthetic polymers. In order to encapsulate hydrophilic
molecules as proteins or nucleic acids, it is necessary to opti-
mize the polymeric composition and the synthesis method.
In this process, a high encapsulation efficiency, maintenance
of the biological activity of the encapsulated biomolecule, and
obtaining of an adequate release pattern have to be achieved
[73–75]. Several delivery systems of BMP2 (and other growth
factors, GFs) using polymeric particles have been described
in the literature. Most of them are microparticulated systems
using the biocompatible and biodegradable PLGA copoly-
mer as main component [76, 77]. Taking into account the
incorporation of BMP2 to the carrier system, encapsulation
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) to obtain PLGA micro/nanoparticles. Depending on the
synthesis conditions (stabilizers, solvents and mixing procedure) it is possible to obtain micro-nanospheres with a uniformmatrix or micro-
nanocapsules with a core-shell structure. Immunoparticles used for directed delivery can be obtained by attaching specific antibodymolecules
on the particle surface.
is preferred to absorption because the growth factors are
more protected against environmental factors in the medium
and may have better control over the delivery and release to
achieve the desired concentrations in specific site and time
[78].
Normally, if the GFs are related with bone regeneration
processes, nano-microparticles are trapped in a second sys-
tem as hydrogels or tissue engineering scaffolds, which also
play an important role in the release profile of GFs from
these particles [78]. The nano-microparticles have allowed
the development of multiscale scaffold, thereby facilitating
control of the internal architecture and adequate patterns of
mechanical gradients of cells and signaling factors [79].
All steps, from the synthesis method and its characteris-
tics, the encapsulation process, or the final surface modifica-
tion for a targeted delivery, determine the characteristics of
these systems and their main goal: the controlled release of
bioactive GFs.
3.1. Synthesis Methods. It is possible to found several pro-
cedures to encapsulate hydrophilic molecules as proteins
or nucleic acids in polymeric nano/microparticles. Phase
separation [80] or spray drying [81] techniques have been
reported to encapsulate hydrophilic molecules. However, in
the case of proteins, the most normally used procedure
to encapsulate them into PLGA micro- and nanoparticles
is the double-emulsion (water/oil/water, W/O/W) solvent
evaporation technique [75, 82]. A schematic description of
this technique is presented in Figure 2. In a general way,
PLGA is dissolved in an organic solvent and emulsified, using
mechanical agitation or sonication, with water containing
an appropriate amount of protein. Thus, a primary water/oil
(W/O) emulsion is obtained. In the second phase, this
emulsion is poured into a large polar phase leading to an
immediate precipitation of the particles as a consequence
of the polymer shrinkage around droplets of the primary
emulsion. This phase may be composed of a water solution
of a stabilizer (surfactant) or ethanol-water mixtures [83,
84]. After stirring, the organic solvent is rapidly extracted
by evaporation under vacuum. A wide list of different
modifications have been tested in this procedure in order to
obtain a micro/nanocarrier system with adequate colloidal
stability, high encapsulation efficiency, adequate bioactivity,
and, finally, a long-time release profilewith low “initial burst.”
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The goal is to avoid a high amount of protein (>60%) being
released very quickly (24 hours), which is one of the biggest
problems of a controlled release system [76].
3.2. Organic Solvent. Hans and Lowman show different
examples of organic solvents used in multiple emulsion
processes. Normally, dichloromethane (DMC), ethyl acetate,
acetone and their mixtures can be used [82]. In the first step,
a good organic solvent with low water solubility to facilitate
the emulsification process and low boiling point for an easy
evaporation would be the election. However, the structure
of the encapsulated protein molecules can be affected and
denaturation processes and loss of biological activity appear
when they interact with a typical organic solvent as DMC
[73]. Ethyl acetate, on the other hand, exerts less denaturating
effects with a lower incidence on the bioactivity of the
encapsulated proteins [85].
Other important factors related with the organic solvent
are their physical properties that affect how the polymer
tails self-organize in the shell of the emulsion droplets and
modify the nanoparticle morphology and the encapsulation
efficiency [86]. In this way, a higher water solubility of
the organic solvent, that is, ethyl acetate, favors a rapid
solvent removal. Additionally, the solvent removal rate can
be controlled by adjusting the volume of the polar phase as
well as the shear stress during the second emulsification step.
An increase of these two parameters increases the diffusion
rate of ethyl acetate from primary microparticles to outer
aqueous phase, resulting in their rapid solidification [87]. It
also enhances the encapsulation efficiency andminimizes the
contact-time between protein molecules and organic solvent
[88], obtaining at the same time a lower burst effect and a
slower drug release from the microparticles [87].
3.3. Particle Size and Morphology. Particle size is an impor-
tant parameter and one of the main goals of the delivery
polymeric system. Microspheres, from a few micrometers up
to 100 𝜇m, are suitable for oral delivery, mucosal adhesion, or
inside scaffold use, that is, for bone regeneration. Nanoscale
dimension of the carrier offers enhanced versatility when
compared with particles of larger size. This is due to the
fact that they have higher colloidal stability, improved dis-
persibility and bioavailability, more reactive surface and also,
can deliver proteins or drugs inside and outside of the
corresponding cells [89]. BMP2 promotes bone formation
and induces the expression of other BMPs and initiates the
signaling pathway from the cell surface by binding to two
different surface receptors [22]. Therefore, the BMP2 carrier
particles must release it into the extracellular medium. Since
cellular intake of PLGAnanoparticles is very fast, the intaking
process can be limited by an increase in size from nano-
to microparticles [90]. However, the interaction between
particles and cells is strongly influenced by particle size. If
cell internalization is desired, the particle must be comprised
in the submicron scale at an interval between 2 and 500 nm
[91]. Moreover, this size is needed for a rapid distribution
after parenteral administration in order to reach different
tissues through different biological barriers. In addition,
Figure 3: Scanning electron microscopy (SEM) photography of
PLGA nanoparticles obtained by a double emulsion emulsification
procedure.This systemwith spherical shape, low polydispersity, and
nanoscopic scale shows the intended properties for an adequate
physiological distribution and cell internalization.
the intake by macrophages is minimized with a diameter
of nanoparticles under 200 nm and even smaller [82, 92].
As discussed by Yang et al. [93], slight modifications of
the synthesis procedure can suppose drastic effects on the
size or particle morphology and, therefore, in the protein
encapsulation efficiency and kinetic release.
In double emulsion processes, the first emulsification
step largely determines the particle size while the second
emulsification step, characterized by the solvent elimination
and polymer precipitation, mainly affects the particle mor-
phology [86]. However, the use of surfactant solutions as
the polar medium of the second emulsification process and
the volume ratio between organic and polar phases in this
step has shown an important influence in the final size [94].
Therefore, the correct election of the organic solvent, the
polymer concentration, the addition of surfactant, and the
emulsification energy allow controlling the size of the system.
The incorporation of poloxamers (F68) in the organic
solvent of the primary emulsification helps to increase the
colloidal stability of the first dispersion by being placed
at the water/oil interface. This reduces the particle size in
comparison with pure PLGA nanoparticles in which the
only stability source comes from electric charge of the
carboxyl groups of the PLGA [95]. It is normal to obtain
spherical micro/nanospheres with a polymeric porous core.
A typical SEM micrograph of PLGA nanoparticles obtained
by W/O/W emulsion using a mixture of organic solvents
(DCM/acetone) and ethanol/water as second polar medium
is shown in Figure 3, in which the spherical shape and
uniform size distribution are the main characteristics. The
outer polymeric shell in the second emulsification step
pushed the water droplets to the inner core according to their
solidification process [96]. This process allows producing
particles like capsules with a core-shell structure in which
the inner core has a low polymer density. Figure 4 shows a
typical core-shell structure in which the polymer precipitates
and shrinks around the water droplets during the solvent
change of the second phase and the subsequent organic
solvent evaporation process [97]. In this case, the process of
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Figure 4: PLGA/poloxamers188 blend nanoparticles. (a) Scanning transmission electron microscopy (STEM) photography; (b) scanning
electron microscopy (SEM) photography. STEM technique allows the analysis of the nanoparticle structure with an internal region with a
low polymer density, which is representative of nanocapsules with core-shell structure.
solidification of the polymer is influenced and determined by
the miscibility of the organic solvent with the second polar
phase and the removal rate.
The polymeric shell often presents channels or pores as
a consequence of the inner water extrusion due to osmotic
forces.This can reduce the encapsulation efficiency and favors
a fast initial leakage with the unwanted “burst release” [93].
This modification of internal structure of the particles is
usually indicated assigning the term “nanosphere” to the
system with a core consisting of a homogeneous polymer
matrix. The bioactive agent is dispersed within them, while
the core-shell structure would be similar to a “nanocapsule”
where the biomolecule is preferably in the aqueous cavity
surrounded by the polymeric shell [78] (see Figure 2).
3.4. Stabilizer Agents
3.4.1. Colloidal Stability. The double emulsion method nor-
mally requires the presence of stabilizers in order to confer
colloidal stability during the first emulsification step, to
prevent the coalescence of the emulsion droplets, and, later,
tomaintain the stability of the final nano/microparticles [98].
Polyvinyl alcohol (PVA) and PEO derivate as poloxamers
(also named pluronics) have been used inmost cases [83, 94].
Others include natural surfactants, such as phospholipids
[99, 100]. In some cases, it is possible to avoid surfactants
if the particles have an electrostatic stability contribution,
that is, from the uncapped end carboxyl groups of the PLGA
molecules [101].
As it has been previously commented, PVA and polox-
amers have shown their efficiency in synthetizing both nano-
and microparticles, affecting not only the stability of the
systems but also their size and morphology. Thus, a size
reduction effect has been found using PVA in the external
water phase, affecting at the same time the surface porosity,
mainly in microsized particles [94]. A comparative study
between this and phospholipids (di-palmitoyl phosphaty-
dilcholine, DPPC) as stabilizers showed that DPPC could
be a better emulsifier than PVA to produce nano- and
microparticles. With this method, a much lower amount of
stabilizer was needed to obtain a similar size. In the same
study, a higher porosity on the particle surface for the PVA
emulsified nanospheres was shown [99].
On the other hand, the combination of PLGA with
poloxamers has shown positive effects for the nano- and
microsystems in terms of stability [102]. The use of these
surfactants in the first or second steps of the W/O/W
emulsion procedure leads to different situations. Thus, if
poloxamers are blended with PLGA in the organic phase
of the primary emulsification, an alteration of the surface
roughness is obtained. However, if these are added in the
inner water phase, an increase of porosity is found [83]. In
addition, their inclusion in the polar phase of the second
emulsification step also generates hydrophilic roughness
surfaces. A quantification of this is shown in Figure 5, in
which the electrophoretic mobility of both PLGA pure and
PLGA/pluronic F68 nanoparticles is measured as a function
of the pH of the medium. The observed dependence with
this parameter is a consequence of the weak acid character
of the PLGA carboxyl groups. When poloxamer molecules
are present at the interface, a systematic reduction ofmobility
was found as a consequence of the increase in the surface
roughness. The hydrophilic surfactant chains spread out
towards the solvent originating a displacement of the shear
plane and the consequent mobility reduction [95, 101].
The final PLGA particle size is primarily controlled by
electrostatic forces and is not significantly affected by the
presence or nature of poloxamer stabilizers [101]. The recog-
nition of the nanocarriers by the mononuclear phagocytic
system (MPS) can be significantly altered if the surface of
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Figure 5: Electrophoretic mobility versus pH for PLGA nano-
particles with different characteristics. (󳶃) PLGA, (◼) PLGA/polox-
amer188 blend, and (∙) PLGA covered by Immuno-𝛾-globulin. The
different surface composition affects the electrokinetic behaviour
of bare nanoparticles. Surface charge values were screened by the
presence of nonionic surfactant as poloxamers, or, in a higher
extension, by the presence of antibody molecules attached on the
surface.
colloidal particles is modified by using PEO block copoly-
mer of the poloxamer molecules. The steric barrier given
by these surfactant molecules prevents or minimizes the
adsorption of plasma protein and decreases the recognition
by macrophages [103]. The size of microspheres is also
unaffected by the coencapsulation of poloxamers. The sys-
tem containing poloxamer-PLGA blends drive to an inner
structure displaying small holes and cavities in relation with
microspheres of pure PLGA with a compact matrix-type
structure [83].
Microparticles formulated by poloxamer in the second
polar medium have completely different surface than the
PVA ones, almost without pores [94]. A comparison between
different poloxamers shows that the hydrophilic-lipophylic
balance (HBL) of the surfactant plays a crucial role determin-
ing the surfactant-polymer interactions and controlling the
porosity and roughness of the nano-microparticles [83, 104].
In a similar manner to surfactants, polymer character-
istics, like the hydrophobicity grade, the molecular weight
or the hydrolysis degradation rate, can strongly influence
the particlemorphology.Therefore, the polymer composition
of the particles greatly affects its structure and properties.
This is why it is usual to use other polymers in order to
modify the behavior and application of the particles. In
this way, polyethylene glycol (PEG) of different chain length
is frequently used to modify the surface characteristics.
With PEG, particles are more hydrophilic and with rougher
surfaces which affects the MPS action by increasing the
circulating-time and half-life in vivo, like the presence of PEO
chains [105]. Additionally, PEG chains also provide colloidal
stability via steric stabilization. Pegylated-PLGA nano- or
microparticles can be normally obtained by using in the
synthesis method PLGA/PEG di- and triblock copolymers
[58, 59, 75]. Natural polymers as chitosan, besides modifying
the hydrophobicity-hydrophilicity ratio of the surface, also
confer them a mucoadhesive character [106].
3.4.2. Encapsulation Efficiency and Bioactivity. Furthermore,
the use of stabilizers (surfactants or polymers) also influ-
ences the encapsulation efficiency and the protein stability.
In fact, for the W/O/W solvent evaporation process, the
chlorinated organic solvent used for the first emulsification
could degrade protein molecules encapsulated in this step
if they come into contact with the organic/water interface,
causing their aggregation or denaturation [107].Thepolymer-
protein interaction, the shear stress for the emulsification
process, and the pH reduction derived from PLGA polymer
degradation can also produce the same situation with the
subsequent loss of biological activity of the encapsulated
biomolecules. Different strategies to prevent it have been
used. For example, an increase of the viscosity around protein
molecules can help to isolate them from their microenviron-
ment [108]. In this way, viscous products, such as starch, have
been used to prevent protein instability [109]. These authors
coencapsulate BMP2 with albumin inside starch microparti-
cles using other biodegradable polymer, poly-𝜀-caprolactone,
instead of PLGA. The BMP2 retained its bioactivity. Despite
a low encapsulation rate, beside an initial burst followed
by an uncompleted release, the amount of BMP2 needed
at the beginning was lower [109]. The combination of PEO
surfactants with PLGA (blended in the organic phase) can
also preserve the bioactivity of microencapsulated proteins
[110] or nucleic acids [84].
However, in most cases, the coencapsulation of GFs
with other biomolecules was the preferred strategy. Thereby,
serum albumins (SA) have shown the capacity to limit the
aggregation-destabilization of several proteins incited by the
water/organic solvent interface of the primary emulsification
process [111, 112]. White et al. encapsulated lysozyme inside
PLGA-PEG microparticles. In addition to the protective
function, they also observed an important increase of the
entrapment efficiency when human SA was coencapsulated
with lysozyme and BMP2 [59]. d’Angelo et al. used heparin
as stabilizer because it forms a specific complex with several
GFs, stabilizes their tridimensional structure, and promotes
their bioactivity. An encapsulation efficiency of 35% was
increased to 87% using bovine SA as a second stabilizer to
encapsulate two natural proangiogenic growth factors inside
PLGA-poloxamer blended nanoparticles.The in vitro cellular
assays showed the preservation of the biological activity of
GFs up to one month [56].
The use of more hydrophilic surfactants (poloxamers)
or polymers (PEG) in the inner water phase or blended
with PLGA in the organic phase of the primary emulsion
reduces the interaction of encapsulated proteins with the
hydrophobic PLGA matrix. This prevents disrupting the
structure of the protein molecules and helps, at the same
time, to neutralize the acidity generated by the hydrolytic
degradation of the PLGA [113]. In some cases, the combina-
tion of several stabilizers, such as poloxamers, trehalose, and
sodium bicarbonate, has been shown to preserve the integrity
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of encapsulated proteins but it also reduces the encapsulation
efficiency [114].
As a general rule, encapsulation efficiency increases with
the size of the particles [82]. Additionally, the adequate sta-
bilization of the primary emulsion by amphiphilic polymers
and a rapid solidification (precipitation) of polymer in the
second step are favorable parameters for enhancing protein
entrapment efficiency in the W/O/W emulsion technique
[87].
The tendency of BMP2 to interact with hydrophobic
surfacesmay decrease the loss of encapsulated protein during
the extraction of the solvent phase. This favors a higher
entrapment but it lowers the later extraction [58]. An optimal
protein encapsulation is obtained when pH of the internal
and external water phases is near the isoelectric point of the
protein [92]. Blanco and Alonso [83] observed a reduction
in the protein encapsulation efficiency when poloxamer was
coencapsulated in the primary emulsion. This highlights the
main role played by the protein-polymer interaction in the
encapsulation efficiency and the later release process. How-
ever, too much emulsifier may also result in a reduction of
the encapsulation efficiency [99]. Therefore, an equilibrium
between the emulsification powder of the surfactant and their
concentration is needed.
3.5. Release Profile. The release profile represents one of the
most important characteristics of a nano/micro particulate
carrier system since their development has a main final
objective: the adequate release of the encapsulated bioactive
molecules to reach the desired clinical action.
The release pattern of protein encapsulated in PLGA
micro/nanoparticles can present different behavior. It is
possible to find a continuous release when the diffusion
of the biomolecule is faster than the particle erosion. This
process involves a continuous diffusion of the protein from
the polymer matrix before the PLGA particle is degraded
in lactic and glycolic acid monomers by hydrolysis [74]. A
biphasic release characterized by an initial burst at or near
the particle surface followed by a second phase in which
protein is progressively released by diffusion has also been
described.The second phase can be enhanced by bulk erosion
of PLGA shell and matrix which results in an important
increase of pores and channels [75]. A third triphasic release
profile has been found when a lag release period occurs
after initial burst and until polymer degradation starts [115].
Finally, it is possible to obtain an incomplete protein release
as a consequence of additional factors related with the
protein-polymer interaction or protein instability. Figure 6
illustrates the different release profiles previously described.
The optimal carrier system should be capable of releasing
a controlled concentration gradient of growth factors in
the appropriate time, preventing or at least reducing or
controlling the initial burst effect [116]. A controlled initial
burst followed by a sustained release significantly improves
the in vivo bone regeneration [117–119].
Giteau et al. [108] present an interesting revision on “How
to achieve a sustained and complete release from PLGA
microparticles.” They begin by analyzing the influence of the

























Figure 6: Release profiles. (I) BSA release from PLGA nanoparti-
cles with high initial burst release; (red dots line) biphasic model
combining a moderate initial burst and a subsequent sustained
release; (blue dash line) triphasicmodel with a lag of release between
both initial and sustained release phases; (dash-dot green line)
incomplete release.
and highlight the significance of the centrifugation cleaning
process or the releasemedium volume. Adjusting to adequate
values the centrifugation speed or the buffer volume, it
is possible to separate micro/nanoparticles from protein-
containing release medium in a very easy way.This allows for
stable and reproducible release patterns. On the other hand,
to ensure a better protein release profile, modification of the
microparticle formulation and microencapsulation process
in order to preserve protein aggregation has to be performed.
Protein stability has to be maintained by preventing the
formation of harmful medium. For example, the synthesis
formulation can be modified to use more hydrophilic poly-
mers, since they have been shown to reduce the initial burst
and to deliver bioactive proteins over long time periods.
The most relevant strategies are referenced below. Drug
release from PLGA nano/microparticles can be controlled
by the polymer molecular weight and the relation between
monomers (lactide/glycolide) so that an increase in gly-
colic acid accelerates the weight loss of polymer due to
the higher hydrophilicity of the matrix [75]. A mixture
of different PLGA nanoparticles obtained using 50 : 50 and
75 : 50 latide/glycolide ratio has shown a great potential for
protein drug delivery with a higher initial burst from PLGA
50 : 50. A slow release period has been observed for PLGA
75 : 50 encapsulating a glycoprotein (𝛼-1-antitrypsin) with
clinic activity in some pulmonary diseases [60].
On the other hand, a faster erosion of the microspheres
with reduction in the PLGA molecular weight due to the
facility of water penetration and the subsequent polymer
degradation has been described [83]. Schrier et al. working
withmicrospheres prepared by w/o/w using different types of
PLGA analyzed the important role of the molecular weight,
lactide-glycolide relation, and acid residues [57].The amount
of rhBMP2 adsorbed on the microparticle surface increased
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with the hydrophobicity of the polymer. At the same time, the
release was in correlation with the degradation profile of the
different polymers [57].
Thus, the use of more hydrophilic polymers reduces the
hydrophobic protein-polymer interaction. This effect favors
a more homogeneous distribution in the polymer matrix
and increases the water uptake in the microspheres. Thus,
the release rate of rhBMP2 encapsulated in microspheres
composed by a PEG-PLGA di-block copolymer is increased
with the PEG content of the polymer matrix [58]. A similar
result was obtained using PLGA-PEG-PLGA triblock copoly-
mers [59]. In this case, modifying the monomer relation
(lactide-glycolide) in the PLGA and increasing the amount
of PLGA-PEG-PLGA in the formulations, the release profile
of BMP-2 coencapsulated with human SA in microespheres
was adjustable. Similarly, the interaction of lysozyme with
poloxamer 188 before their encapsulation produces a sus-
tained release over 3 weeks without any burst effect. In the
same line, using PLGA-PEG-PLGA as polymer, a sustained
release of bioactive lysozime was extended over 45 days when
the protein was complexed with poloxamer 188 previously to
the encapsulation [120]. However, the presence of PEG300 as
an additive of the inner phase of microparticles during the
encapsulation process also influences the protein distribution
and the release profile. In this case there is a decrease of the
initial burst but with less overall release [58].
On the other hand, the use of PLGA-poloxamers blends
is useful to obtain a sustained release for more than one
monthwithout any incidence in the high initial burst [56, 92].
However, for an encapsulated plasmid inside nanoparticles
obtained by PLGA-poloxamer blends, the hydrophobicity of
the surfactant allows prolonging the release up to 2 weeks in a
controlledmanner.Moreover, a complete release was reached
for the PLGA-poloxamer blend instead PLGA nanoparticles,
in which the maximum release was around 40% [84].
PLGA and poloxamers (pluronic F68) blends can also be
used to obtain nanocomposite vesicles by a double emulsion
process. These vesicles are suitable for the encapsulation of
hydrophobic and hydrophilic molecules. The presence of
pluronic affects the colloidal stability of the vesicles and the
release pattern of the encapsulated molecules. These vesicles
present a wall of 30 nm and the drug is encapsulated in the
presence of the poloxamer [121].
Other strategies include the use of different compounds to
increase the release time.Thus, BMP2 encapsulated in PLGA-
PVA nanoparticles (around 300 nm) showed higher encapsu-
lation efficiency and a short-time release profile with a very
high initial burst. However, with the same synthesis proce-
dure (w/o/w) but using PHBV (Poly(3 hydroxybutyrateco-
3-hydroxivalerate)), BMP7 loaded nanocapsules had less
encapsulation efficiency despite a long-time delivery. Nev-
ertheless, the maximum released amount was lower. This
difference in the release profile was due to the difference
in hydrophilicity and degradation rates of both polymers
[122]. Similarly, PLGA-poloxamer blend nanoparticles were
superficially modified by introducing chitosan in the second
step of the synthesis.This method showed a sustained release
profile for up to 14 days without any initial important burst.
In this case, a recombinant hepatitis B antigen was used
[106]. Moreover, the use of heparin conjugated with PLGA
porous microspheres has also been described to obtain a
long-time delivery system reducing at the same time the
initial burst. In these systems, heparin was immobilized onto
the nano/microparticle surface. The release was controlled
by using the binding affinities of heparin to several growth
factors including BMP2. In this case, the initial burst was
reduced to 4–7% during first day followed by a sustained
release of about 1% per day [51–53].
The initial burst release may be attenuated by the
fabrication of double-wall microspheres, that is, core-shell
microparticles. The presence of a PLA shell reduces the
release rate of BSA encapsulated in the PLGA core and
extends the duration of the release profile up to two months.
Moreover, an increase in the PLA molecular weight influ-
ences the rate of particle erosion, which further slows the
protein release [123].
The modification of the viscosity in the environment
of microparticles additionally influences the release pattern.
Viscosity can control the burst at earliest time point and
promote a sustained release. This situation has been shown
for rhBMP2-PLGA microspheres embedded in a chitosan-
thioglycolic acid hydrogel (Poloxamer 407) [124]. Yilgor et
al. also incorporated the nanoparticles of their sequential
delivery system into a scaffold composed by chitosan and
chitosan-PEO [54]. In other work, PLGA/PVA microspheres
with encapsulated BMP2 were combined with different
composite biomaterials (gelatin hydrogel or polypropylene
fumarate). The sustained release of the bioactive molecule
was extended over a period of 42 days. In vivo results indicate
the importance of the composite characteristics. In this case,
an enhanced bone formation was obtained when the PLGA
microparticles were incorporated into the more hydrophobic
matrix (polypropylene fumarate) [125, 126].
Finally, Table 2 summarizes important information about
different parameters related to the use of PLGA based
nano- ormicroparticles to encapsulate, transport, and release
growth factors (mainly BMP2).
3.6. Gene Therapy for Bone Tissue Engineering: Directed
Delivery. In the last years, gene therapy has begun to play
a role in bone tissue regeneration becoming an alternative
method for the delivery of BMP2 [127, 128]. Thus, the genes
encoding a specific protein can be delivered to a specific cell,
rather than the proteins themselves. To reach this purpose,
an efficient gene vector is necessary. Viral vectors possess the
best transfection efficiency but numerous disadvantages, the
most notable of them being the risk of mutagenesis. Nonviral
vectors elude these problems but with a significant reduction
in the transfection rate [129].Therefore, intracellular delivery
of bioactive agents has become the most used strategy for
gene therapy, looking for the adequate transfection and
consequent expression of the desired protein [79].
PLGA microspheres obtained by a w/o/w double emul-
sion process have been used by Qiao et al. to entrap plasmid-
BMP2/polyethyleneimine nanoparticles. In this case, a sus-
tained release of these nanoparticles until 35 days without ini-
tial burst was found resulting in differentiation of osteoblast
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Table 2: Nano/microparticles systems to encapsulate GFs, mainly BMP2 growth factor. Most of them are in the microscopic scale and
were used to be entrapped into scaffold of different characteristics. PVA has been the more used surfactant-stabilizer. It is possible to find
both, encapsulation and surface adsorption of the growth factors with high-moderate efficiency. The use of heparin as stabilizer reduces
significantly the initial burst release, favoring a sustained release in the time. The bioactivity of the GF was preserved in most of the systems
and coencapsulation with other biomolecules seems to have a similar effect than the use of surfactants as stabilizers.
Polymers Stabilizer Size Encapsulation% EE Release Biological activity Reference
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Table 2: Continued.
Polymers Stabilizer Size Encapsulation% EE Release Biological activity Reference
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promoted by the correct transfection of the delivered bio-
functional BMP2-DNA [130].
In spite of the general caution with gene therapy, the
genetic delivery of BMP2 has the potentiality of a better safety
compared with the delivery of large amounts of recombinant
protein [131]. Lu et al. specify the urgent need to developmore
efficient delivery nanoparticles and transfection methods in
order to apply the nonviral vectors in stem cell engineering
and bone regeneration. Although enhanced bone formation
has been shown in several recent studies using genes such
as HIF-1𝛼 and miRNAs, new genetic sequences will be
discovered and used in bone engineering in the near future
that will most likely change our perspective [132].
PLGA nanospheres represent a well-studied biomolecule
delivery system that could be applied to cell targeting, in
order to enhance the delivery of specific proteins or nucleic
acids inside or near the bone engineering reference cells, that
is, mesenchymal stem cells [133].The targeting properties can
be supplied by a ligand functionalization strategy: modifica-
tion of the surface structure of the nanocarrier by conjugating
a cell-specific ligand to direct the release of encapsulated
biomolecules preferably in close association with the target
cells [134].The use of pegylated nanoparticles with a covalent
attachment of different ligands is reported as a potential
technique to deliver bone cell-specific biomolecules for bone
engineering [135].
Specific antibodies that recognize surface receptors in
these cells could be covalently coupled to the surface of PLGA
nanoparticles, obtaining “immunonanoparticles.” There are
several examples of antibody immobilization on surface
of PLGA nanoparticles. Kocbek et al. demonstrated the
specific recognition of breast tumor cells by a specific mono-
clonal antibody attached on PLGA fluorescent nanoparticles
obtained by W/O/W emulsion process [136]. For the surface
covalent attachment, they used a more simple carbodiimide
method, which promotes the formation of an amide bond
between free carboxylic end groups of PLGA nanoparticles
and primary amine groups of the antibody molecule [81].
This procedure can be highly influenced by the presence
of stabilizers frequently used to confer colloidal stability
to nanoparticles. The electrophoretic mobility of PLGA
nanoparticles with an antibody (immuno-𝛾-globuline anti-
human C-reactive protein) covalently attached on the surface
is shown in Figure 5. It is necessary to remark the drastic
decrease in the mobility values of the antibody-modified
nanoparticles with respect to bare PLGA nanoparticles,
which could imply low colloidal stability and the subse-
quent aggregation of the nanosystem. Santander-Ortega et
al. proposed a lower antibody loading in which the bare
PLGA patches must be coated by a nonionic surfactant in
order to obtain immunoreactive stable nanoparticles [95].
Ratzinger et al. indicated that the presence of high polox-
amer concentrations decreased the coupling efficiency to
carboxylic end groups in PLGA nanoparticles, showing that
an equilibrium that combines sufficient stability and the best
coupling efficiency is necessary [98]. To prevent this problem,
Cheng et al. synthetized carboxyl functionalized PLGA-
PEG block copolymer, attaching a specific aptamer to the
surface of pegylated nanoparticles via carbodiimide method.
In this work, an enhanced drug delivery to prostate tumors
has been shown in comparison to equivalent nontargeted
nanoparticles [137].
3.7. Scaffolds. The data reported in the literature indicate
that PLGA micro/nanoparticles are promising to achieve
a sustained, spatial, and temporally controlled delivery of
growth factors required for cell growth and cell differen-
tiation. They can be incorporated with cells in solid scaf-
fold or injectable hydrogels [73]. Scaffolds are porous 3D
structures normally used to improve tissue-engineered bone
[28]. According to Tian et al. [45], a scaffold designed
with this objective must have (1) appropriate mechanical
strength to support the growth of new bone; (2) appropriate
porosity to allow ingrowth of bone-related cells; (3) good
biocompatibility allowing the growth of cells on its surface
without being rejected by the body; and (4) low toxicity to
cells and tissues surrounded and (5) must be able to induce
osteogenic differentiation of bone-related stem cells and (6)
be biodegradable with nontoxic degradation products that
can be eventually replaced by new bone. Additionally, the
scaffold for bone regeneration must maintain the delivery or
release of BMP (growth factors) “in situ” for a long time. In
this way, nano/microparticles inside scaffolds are being used
to release an adequate flow of these signaling biomolecules
and preserve their functional structure [138]. The incorpo-
ration of colloidal micro/nanoparticles into fibrous scaffolds
adds in the possibility of multiple drugs loading. However,
this multidrug system could also involve a decrease of
the mechanical properties of the structure and a possible
loss of nanoparticles entrapped between the fibers [139].
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Considering that the in vivo half-life of most biomolecules,
especially proteins, is relatively short, it is essential that
bioactive scaffolds maintain a desired concentration “in situ”
to direct tissue regeneration. To do so, an initial release of
the encapsulated growth factor in the first hours to quickly
get an effective therapeutic concentration followed by a
sustained long-time release profile is required [139]. Most of
the polymeric particles inserted in scaffold structures are in
a micron-scale. The main objective of these microparticles
is the protection and temporary control of growth factor
delivery. However, given the porosity of these structures,
nanoparticles and especially particles of a few microns may
become more important since it is possible to design systems
with a simple and easy diffusion through the structure. This
process could allow the specific recognition of a particular
cell type, releasing their encapsulated BMPs in the same
environment and helping their differentiation to cell/bone
tissue. In any case, the larger-size microspheres might not
necessarily be useless for bone regeneration scaffolds. As the
microspheres gradually degrade, the space they occupied will
be conducive to ingrowth of tissue. In addition to affecting
the compressionmodulus of scaffolds because of their hollow
feature, the particle size of microspheres can also influence
the release of rhBMP2 [45].
4. Conclusion
The use of polymeric particles using PLGA is a promising
system for a spatially and temporally controlled delivery of
growth factors that promote cell growth and differentiation
in bone engineering and regeneration by means of their
incorporation beside cells into solid scaffold or hydrogels.
The PLGA is widely used for its biodegradability and
biocompatibility and is approved by FDA and the European
Medicines Agency for use in drug delivery systems supplied
via parenteral. On the other hand, BMPs are potent growth
factors for bone repair and specifically BMP2 shows excellent
ability to induce bone formation of adequate quality. The
procedure for synthesizing PLGA nano- or microparticles
can be modified in their different variables to obtain systems
with controlled size, in which it is possible to encapsulate
hydrophobic or hydrophilic molecules, with an adequate col-
loidal stability and the possibility of surface functionalization
for targeted delivery.
With this scenario, an optimization of methods and com-
ponentsmust balance the structure andmorphology of PLGA
micro/nanoparticles in order to achieve high encapsulation
efficiency of BMP2 and looking for a main goal: control of
delivery, reducing the initial burst, and reaching a sustained
release profile, preserving the biological activity, and directed
to the target cells tominimize the clinical amount needed and
allowing a correct bone tissue regeneration.
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J. Alblas, “Bone morphogenetic protein-2 plasmid DNA as a
substitute for bone morphogenetic protein-2 protein in bone
tissue engineering,” Tissue Engineering Part A, vol. 19, no. 23-24,
pp. 2686–2692, 2013.
[129] J. Fischer, A. Kolk, S. Wolfart et al., “Future of local bone
regeneration—protein versus gene therapy,” Journal of Cranio-
Maxillofacial Surgery, vol. 39, no. 1, pp. 54–64, 2011.
[130] C. Qiao, K. Zhang, H. Jin et al., “Using poly(lactic-co-glycolic
acid) microspheres to encapsulate plasmid of bone morpho-
genetic protein 2/polyethylenimine nanoparticles to promote
bone formation in vitro and in vivo,” International Journal of
Nanomedicine, vol. 8, pp. 2985–2995, 2013.
[131] C. H. Evans, “Gene delivery to bone,” Advanced Drug Delivery
Reviews, vol. 64, no. 12, pp. 1331–1340, 2012.
[132] C.-H. Lu, Y.-H. Chang, S.-Y. Lin, K.-C. Li, andY.-C.Hu, “Recent
progresses in gene delivery-based bone tissue engineering,”
Biotechnology Advances, vol. 31, no. 8, pp. 1695–1706, 2013.
[133] T.N.Vo, F. K. Kasper, andA.G.Mikos, “Strategies for controlled
delivery of growth factors and cells for bone regeneration,”
18 BioMed Research International
Advanced Drug Delivery Reviews, vol. 64, no. 12, pp. 1292–1309,
2012.
[134] W. Ji, H. Wang, J. J. J. P. van den Beucken et al., “Local delivery
of small and large biomolecules in craniomaxillofacial bone,”
Advanced Drug Delivery Reviews, vol. 64, no. 12, pp. 1152–1164,
2012.
[135] V. Luginbuehl, L. Meinel, H. P. Merkle, and B. Gander, “Local-
ized delivery of growth factors for bone repair,” European
Journal of Pharmaceutics and Biopharmaceutics, vol. 58, no. 2,
pp. 197–208, 2004.
[136] P. Kocbek, N. Obermajer, M. Cegnar, J. Kos, and J. Kristl, “Tar-
geting cancer cells using PLGA nanoparticles surface modified
with monoclonal antibody,” Journal of Controlled Release, vol.
120, no. 1-2, pp. 18–26, 2007.
[137] J. Cheng, B. A. Teply, I. Sherifi et al., “Formulation of func-
tionalized PLGA-PEG nanoparticles for in vivo targeted drug
delivery,” Biomaterials, vol. 28, no. 5, pp. 869–876, 2007.
[138] C. Romagnoli, F. D’Asta, andM. L. Brandi, “Drug delivery using
composite scaffolds in the context of bone tissue engineering,”
Clinical Cases inMineral and BoneMetabolism, vol. 10, no. 3, pp.
155–161, 2013.
[139] D. Puppi, X. Zhang, L. Yang, F. Chiellini, X. Sun, and E.
Chiellini, “Nano/microfibrous polymeric constructs loaded
with bioactive agents and designed for tissue engineering
applications: a review,” Journal of Biomedical Materials Research
Part B: Applied Biomaterials, vol. 102, no. 7, pp. 1562–1579, 2014.






















































Materials Science and Engineering
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Smart Materials 
Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Metallurgy
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Materials
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
N
a
no
m
a
te
ri
a
ls
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal ofNanomaterials
